The Exciting Research That May Cure Parkinsons

Parkinson’s disease is on the rise. According to the World Health Organization, the prevalence of the neurodegenerative disease has doubled worldwide since the turn of the century. Is there anything we can do about it? Read more about prof. Saarma’s research and GeneCode’s mission here: https://www.freethink.com/health/the-exciting-research-that-may-cure-parkinsons

Read More

Genecode set to expand our GDNF Mimetics Platform

At GeneCode, we’re thrilled to share a major milestone in our research journey. With the recent €1.6M grant from Enterprise Estonia (EAS), we are set to expand our GDNF Mimetics Platform to address ALS, Retinitis Pigmentosa, and Inflammatory Bowel Disease. Read more

Read More

Top 5 Best BioTech Companies to Watch

GeneCode has been named one of the TOP 5 best biotech companies to watch in 2024 by The Silicon Review! GeneCode research group led by Prof. Dr. Saarma is investigating the structure, biology, and therapeutic potential of neurotrophic factors. We specifically study the GDNF family neurotrophic factors and their receptors. Prof. Dr. Saarma’s exclusive interview is available…

Read More

GeneCode – Enterprise Estonia

GeneCode’s R&D project has received tremendous backing from Enterprise Estonia, and we are grateful for their critical support. In collaboration with them, we have taken time to reflect on our journey with them and Argobio and look ahead to the future. https://investinestonia.com/follow-the-science-end-up-in-estonia/

Read More

European Innovation Council (EIC) Accelerator

European Innovation Council (EIC) Accelerator is providing € 16 million to support the development of a drug and treatment to slow the progression in Parkinson’s disease. The funding to GeneCode for the Kevad Bio project developed in collaboration with Argobio is split into a € 1.7 million grant and € 14.3 million in equity investments. This…

Read More

Launch of WHO’s Parkinson disease technical brief

Launch of WHO’s Parkinson disease technical brief. Globally, the prevalence of Parkinson disease (PD) has doubled in the past 25 years with global estimates in 2019 showing over 8.5 million individuals living with PD. Disability and death due to PD are increasing faster than for any other neurological disorder. Current estimates suggest that, in 2019,…

Read More

GeneCode and Argobio Partners

We are very honored to share the news of the GeneCode and Argobio Partners on Parkinson’s Disease in Argobio’s First Announced Research Agreement. Read more: https://www.argobiostudio.com/en/news/argobio-and-genecode-partner-on-parkinsons-disease-in-argobios-first-announced-research-agreement#news

Read More